Listen to Kerry and Luisa discuss the findings of their analysis of the latest remuneration packages for the executive committees: Pharma CEO remuneration. 2026 brings greater alignment with shareholders as LTIPs are more closely linked to “total shareholder return”. This is largely driven by CEO changes at Novo Nordisk and Sanofi. Interesting snippets across the companies are revealed. The scores are in for the 2023 total compensation packages and the 2025 annual bonus delivery. The best share price performance over 2023-25 was delivered at Eli Lilly (+194%) where remuneration scorecards have the smallest number of metrics, pipeline has the second highest weight in the annual bonus, LTIP is linked to “total shareholder return” only and the highest proportion of remuneration is delivered in equity.